Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
Abstract Background A decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12944-019-1099-z |
id |
doaj-0a1f41617a5f409383e4b0c6c1c28308 |
---|---|
record_format |
Article |
spelling |
doaj-0a1f41617a5f409383e4b0c6c1c283082020-11-25T02:48:50ZengBMCLipids in Health and Disease1476-511X2019-09-0118111410.1186/s12944-019-1099-zLong-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysisPeter P. Toth0Craig Granowitz1Michael Hull2Amy Anderson3Sephy Philip4CGH Medical CenterAmarin Pharma IncOptumOptumAmarin Pharma IncAbstract Background A decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured long-term statin persistence in patients with high CV risk. Methods This retrospective administrative claims analysis of the Optum Research Database included patients aged ≥ 45 years with diabetes and/or atherosclerotic CV disease (ASCVD) who had a statin prescription filled in 2010. It included an elevated triglycerides (TG) cohort of patients with index date in 2010 and TG ≥ 150 mg/dL (n = 23,181) and a propensity-matched comparator cohort with TG < 150 mg/dL and high-density lipoprotein cholesterol > 40 mg/dL (n = 23,181). Both cohorts were followed for ≥ 6 months up to March 2016. Results The probability of remaining on a prescription fill for index statin therapy was 47% after 1 year and 19% after 5 years in both cohorts. Statin persistence was worse among women than men, and among younger versus older patients (P < 0.001 for all comparisons). After 5 years, the probability of remaining on a prescription fill for index statin was < 25% across all subgroups assessed including patients with and without baseline revascularization, heart failure, peripheral artery disease and renal disease. Similar results were observed in a subcohort analysis of patients with TG 200–499 mg/dL. Conclusions Long-term statin persistence after 5 years is alarmingly low (< 25%) and is a public health concern.http://link.springer.com/article/10.1186/s12944-019-1099-zStatinTriglyceridesPersistenceDiscontinuationAtherosclerotic cardiovascular diseaseDiabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Peter P. Toth Craig Granowitz Michael Hull Amy Anderson Sephy Philip |
spellingShingle |
Peter P. Toth Craig Granowitz Michael Hull Amy Anderson Sephy Philip Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis Lipids in Health and Disease Statin Triglycerides Persistence Discontinuation Atherosclerotic cardiovascular disease Diabetes |
author_facet |
Peter P. Toth Craig Granowitz Michael Hull Amy Anderson Sephy Philip |
author_sort |
Peter P. Toth |
title |
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis |
title_short |
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis |
title_full |
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis |
title_fullStr |
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis |
title_full_unstemmed |
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis |
title_sort |
long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis |
publisher |
BMC |
series |
Lipids in Health and Disease |
issn |
1476-511X |
publishDate |
2019-09-01 |
description |
Abstract Background A decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured long-term statin persistence in patients with high CV risk. Methods This retrospective administrative claims analysis of the Optum Research Database included patients aged ≥ 45 years with diabetes and/or atherosclerotic CV disease (ASCVD) who had a statin prescription filled in 2010. It included an elevated triglycerides (TG) cohort of patients with index date in 2010 and TG ≥ 150 mg/dL (n = 23,181) and a propensity-matched comparator cohort with TG < 150 mg/dL and high-density lipoprotein cholesterol > 40 mg/dL (n = 23,181). Both cohorts were followed for ≥ 6 months up to March 2016. Results The probability of remaining on a prescription fill for index statin therapy was 47% after 1 year and 19% after 5 years in both cohorts. Statin persistence was worse among women than men, and among younger versus older patients (P < 0.001 for all comparisons). After 5 years, the probability of remaining on a prescription fill for index statin was < 25% across all subgroups assessed including patients with and without baseline revascularization, heart failure, peripheral artery disease and renal disease. Similar results were observed in a subcohort analysis of patients with TG 200–499 mg/dL. Conclusions Long-term statin persistence after 5 years is alarmingly low (< 25%) and is a public health concern. |
topic |
Statin Triglycerides Persistence Discontinuation Atherosclerotic cardiovascular disease Diabetes |
url |
http://link.springer.com/article/10.1186/s12944-019-1099-z |
work_keys_str_mv |
AT peterptoth longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis AT craiggranowitz longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis AT michaelhull longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis AT amyanderson longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis AT sephyphilip longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis |
_version_ |
1724746342627016704 |